An Online-platform to Improve Patient-centered Care During the COVID-19 Pandemic: a GIMEMA Surveillance Program in Hematologic Malignancies

Gruppo Italiano Malattie EMatologiche dell'Adulto

Status: Enrolling

Conditions: Hematologic Malignancies

Treatments: Other: Quality of life assessment

Study type: Observational

Funder types: Other

Identifiers

NCT04581187

GIMEMA-ALLIANCE Platform

Details and patient eligibility

About

This is a national multicenter prospective observational study led by the GIMEMA. The GIMEMA-ALLIANCE Platform is also an online monitoring system for patients with hematologic malignancies aiming at helping hematologists in the early recognition and timely management of problems of their patients. Based on patient's rating of specific items (i.e. on the presence of clinically relevant problems or problems with adherence to therapy or risk of SARS-CoV-2 infection), the Platform will automatically send alerts to the treating hematologist (and/or appointed members of the local Team). Physicians will be free to make any action they feel appropriate for the best care of their patients.

Enrollment: 400 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Diagnosis of any hematologic malignancy according to 2016 WHO classification
• Adult Patients (≥18 years).
• Written informed consent

Exclusion criteria

• Major cognitive deficits or psychiatric problems hampering a self-reported evaluation.
• Not able to read and understand local language